Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas.
["Srour, S A", "Singh, H", "McCarty, J", "de Groot, E", "Huls, H", "Rondon, G", "Qazilbash, M", "Ciurea, S", "Bardelli, G", "Buck, J", "Alousi, A", "Nieto, Y", "Rezvani, K", "Marin, D", "Popat, U", "Hosing, C", "Shpall, E J", "Wierda, W G", "Kantarjian, H", "Champlin, R E", "Cooper, L J", "Kebriaei, P"]
Blood 2020
Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Srour SA(1), Singh H(2), McCarty J(1), de Groot E(3), Huls H(2), Rondon G(1), Qazilbash M(1), Ciurea S(1), Bardelli G(3), Buck J(3), Alousi A(1), Nieto Y(1), Rezvani K(1), Marin D(1), Popat U(1), Hosing C(1), Shpall EJ(1), Wierda WG(4), Kantarjian H(4), Champlin RE(1), Cooper LJ(3), Kebriaei P(1).